Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO
Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...
Arch Resources and CONSOL Energy Merged to form Core Natural Resources (CNR)
ARCH is one of the leading U.S. producers of high-quality metallurgical coal (“met coal”). This is the kind of coal used for ...
Maze Therapeutics targets up to $728 million valuation in US IPO
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
Real estate firms pivot to energy development amid booming data center demand
Brendan Wallace has a lot on his mind lately. Wallace is the co-founder of Fifth Wall Ventures, a nine-year-old proptech ...